Chau Cheng
Investor Relations Contact bij IMMUNOVANT, INC.
Profiel
Chau Cheng is currently the Vice President of Investor Relations at Immunovant, Inc. Prior to this, he worked as the Senior Director of Investor Relations at Immunomedics, Inc. from 2004 to 2020.
From 2020 to 2022, he worked as the VP of Investor Relations and Corporate Communications at CytomX Therapeutics, Inc. Dr. Cheng holds a Master's in Business Administration from The Leonard N Stern School of Business.
Actieve functies van Chau Cheng
| Bedrijven | Functie | Begin |
|---|---|---|
| IMMUNOVANT, INC. | Investor Relations Contact | - |
Eerdere bekende functies van Chau Cheng
| Bedrijven | Functie | Einde |
|---|---|---|
| CYTOMX THERAPEUTICS, INC. | Investor Relations Contact | 01-09-2022 |
| IMMUNOMEDICS, INC. | Investor Relations Contact | 01-12-2020 |
Opleiding van Chau Cheng
| The Leonard N Stern School of Business | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| CYTOMX THERAPEUTICS, INC. | Health Technology |
| IMMUNOVANT, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Immunomedics, Inc.
 Immunomedics, Inc. BiotechnologyHealth Technology Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ. | Health Technology |
